- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04677322
TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET IN PATIENTS WITH HTA (IDI-HTA2020)
OBSERVATIONAL STUDY TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET THROUGH THE MONITORING OF SODIUM IN URINE IN PATIENTS WITH HIGH BLOOD PRESSURE IN THE PRIMARY CARE SETTING
Arterial hypertension is an independent vascular risk factor and a frequent reason for consultation in Primary Care. It generates high cardiovascular morbidity and mortality (stroke, heart disease, kidney failure and other diseases). Moreover, given that it is a modifiable factor and that there are intervention and control measures that would lead to a significant reduction in cardiovascular incidence and morbimortality, it can be stated that ETS is a major public health problem.
The approach to this risk factor can be pharmacological and non-pharmacological. The non-pharmacological approach is based on lifestyle modification. Among the measures aimed at modifying lifestyles is the restriction of daily intake of sodium in the diet. Such restriction enhances the hypotensive effect of pharmacological treatment so that its application and intensification would delay the start of pharmacological therapy, as well as avoid the need to increase the dose of antihypertensive drugs or the number of drugs to be used for the control of hypertension.
In relation to salt intake in the Spanish population, the average is above the figures of less than 5 grams per day recommended by the WHO. Sodium intake can be estimated by determining the 24-hour urine sodium concentration. In addition, there is a positive correlation between systolic and diastolic blood pressure figures and the excretion of sodium in urine.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Cantabria
-
Santander, Cantabria, Spain, 39610
- Centro de salud Astillero
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients over 40 years old.
- Patients diagnosed with HTA (according to criteria ESC/ESH 2018) in a PA consultation or through MAP at the health center.
- In treatment with single, double or triple antihypertensive therapy.
- Patients with ST figures ≥140.
- Patients with TD numbers ≥90.
- Patients with stable antihypertensive treatment or without modifications in the treatment at least in the last month.
- Patients who commit to follow up the study.
- Patients who have given written informed consent.
Exclusion Criteria:
- Patients with decompensated heart failure
- Severe renal failure.
- Decompensated liver disease.
- Taking non-insulin antidiabetic
- Hypertension of pharmacological origin and other causes.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Systolic and diastolic TA values, the upper limit being 140 (systolic) and the lower range 90 (diastolic).
Time Frame: basal
|
basal
|
|
Systolic and diastolic TA values, the upper limit being 140 (systolic) and the lower range 90 (diastolic).
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sodium and potassium levels in 24-hour urine and isolated urine sample, with sodium limits of 20 mEq/L in a random urine sample and 40 to 220 mEq per day.
Time Frame: basal
|
basal
|
|
Sodium and potassium levels in 24-hour urine and isolated urine sample, with sodium limits of 20 mEq/L in a random urine sample and 40 to 220 mEq per day, after educational intervention.
Time Frame: 6 months
|
6 months
|
|
To analyze the use of antihypertensive drugs USING morisk-green test, after educational intervention
Time Frame: 6 months
|
6 months
|
|
To verify compliance with the hyposodium diet and pharmacological treatment through the use of EuroQol-5D questionnaires
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDI-HTA-2020-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arterial Hypertension
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
-
University of Sao Paulo General HospitalRecruitingPulmonary Arterial Hypertension (PAH)Brazil
-
University Hospital, BrestNot yet recruitingPulmonary Arterial Hypertension (PAH)France
-
Shanghai Zhongshan HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Regeneron PharmaceuticalsRecruitingPulmonary Arterial Hypertension (PAH)United States, United Kingdom, Latvia, South Korea
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
University of Sao Paulo General HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)Brazil
Clinical Trials on Adult patients diagnosed and treated for high blood pressure
-
Centre Hospitalier Universitaire de NiceNot yet recruiting
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruiting
-
Hacettepe UniversityRecruitingScleroderma, Localized | Scleroderma | Swallowing | Systemic Sclerosis (SSc) | Scleroderma (Limited and Diffuse)Turkey (Türkiye)
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertensionUnited States
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruiting
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); Solving Kids' Cancer; American Lebanese Syrian... and other collaboratorsActive, not recruitingGlioblastoma Multiforme | Medulloblastoma | Diffuse Intrinsic Pontine Gliomas (DIPG) | High-grade Astrocytoma Not Otherwise Specified (NOS) | CNS Primary Tumor, Not Otherwise Specified (NOS) | Ependymoma, Not Otherwise Specified (NOS)United States
-
Akdeniz UniversityCompletedLumbar Disc Herniation | Lumbar Spinal Stenosis | Lumbar Disc Disease | Lumbar FractureTurkey
-
Central Hospital, Nancy, FranceNot yet recruitingSafety | Antiphospholipid Syndrome (APS) | Thrombotic and Bleeding Events | Direct Oral Anticoagulants (DOACs)Spain
-
Cancer Institute and Hospital, Chinese Academy...Beijing Huanxing Cancer Hospital; Cancer Hospital, Chinese Academy of Medical...RecruitingEarly-stage Breast CancerChina
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioNot yet recruitingBariatric Surgery Candidate